Woodline Partners LP Purchases 25,094 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Woodline Partners LP increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 485,073 shares of the biotechnology company's stock after purchasing an additional 25,094 shares during the period. Woodline Partners LP owned approximately 1.59% of AnaptysBio worth $6,422,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 644 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 936 shares in the last quarter. Rhumbline Advisers lifted its stake in AnaptysBio by 3.8% in the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock valued at $398,000 after acquiring an additional 1,111 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,531 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in AnaptysBio by 21.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,012 shares of the biotechnology company's stock valued at $199,000 after acquiring an additional 2,701 shares in the last quarter.

Wall Street Analyst Weigh In

ANAB has been the topic of several research reports. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a research note on Thursday, May 1st. HC Wainwright restated a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a research note on Tuesday, March 4th. Guggenheim restated a "buy" rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday. Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 target price on the stock. Finally, Wells Fargo & Company boosted their price target on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and a consensus target price of $40.38.

AnaptysBio Trading Up 3.6%

Shares of NASDAQ:ANAB traded up $0.76 during trading on Thursday, hitting $21.66. 347,036 shares of the company were exchanged, compared to its average volume of 607,021. The stock has a market cap of $636.34 million, a price-to-earnings ratio of -3.55 and a beta of -0.20. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The firm has a fifty day moving average price of $19.57 and a two-hundred day moving average price of $18.26.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, research analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its board has initiated a stock buyback plan on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.